The Endocannabinoid System [ECS] and its Role in Metabolic Processes
The Endocannabinoid System: An Overview
‘Marijuana has been used as a medicine for thousands of years with evidence dating back to 2000 BC, but only in the past few decades have scientists truly understood how it works.
What led to this understanding was the discovery of the endocannabinoid system; a unique biological system that facilitates the effects of marijuana within the human body.
The endocannabinoid system is a central regulatory system that affects a wide range of biological processes. It consists of a group of molecules known as cannabinoids as well as the cannabinoid receptors that they bind to.
Although marijuana is a source of over 60 cannabinoids (including THC and CBD), the human body produces a number of cannabinoids as well. These endogenous cannabinoids include anandamide and 2-arachidonoylglycerol (2-AG) and are present in all human beings.
Decades of scientific research on the endocannabinoid system has resulted in the discovery of two types of cannabinoid receptors, CB1 and CB2. These receptors are found in various parts of the body, but are most prominent in the brain and immune system.
Cannabinoid receptors act as binding sites for endogenous cannabinoids as well as cannabinoids found in marijuana. When cannabinoids bind to CB1 or CB2 receptors, they act to change the way the body functions.
While cannabinoid receptors are primarily expressed in the brain and immune system, researchers have identified cannabinoid receptors in a variety of other places as well, including the peripheral nervous system, cardiovascular system, reproductive system, and gastrointestinal and urinary tracts. Cannabinoid receptors continue to be identified in unique parts of the body as research on the endocannabinoid system progresses.’
Full article ~ http://www.truthonpot.com/2013/03/22/the-endocannabinoid-system-an-overview/
Wiki – Endocannabinoid System
‘The endocannabinoid system is a group of neuromodulatory lipids and their receptors in the brain that are involved in a variety of physiological processes including appetite, pain-sensation, mood, and memory; it mediates the psychoactive effects of cannabis and, broadly speaking, includes:
The endogenous arachidonate-based lipids, anandamide (N-arachidonoylethanolamide, AEA) and 2-arachidonoylglycerol (2-AG); these are known as “endocannabinoids” and are physiological ligands for the cannabinoid receptors. Endocannabinoids are all eicosanoids.
The enzymes that synthesize and degrade the endocannabinoids, such as fatty acid amide hydrolase or monoacylglycerol lipase.
The cannabinoid receptors CB1 and CB2, two G protein-coupled receptors that are located in the central and peripheral nervous systems.
The endocannabinoid system has been studied using genetic and pharmacological methods. These studies have revealed that cannabinoids act as neuromodulators for a variety of physiological processes, including motor learning, synaptic plasticity, appetite, and pain sensation.’
Full article ~http://en.wikipedia.org/wiki/Endocannabinoid_system
National Center for Biotechnology Information (NCBI) – The Endocannabinoid System as an Emerging Target of Pharmacotherapy
‘The recent identification of cannabinoid receptors and their endogenous lipid ligands has triggered an exponential growth of studies exploring the endocannabinoid system and its regulatory functions in health and disease. Such studies have been greatly facilitated by the introduction of selective cannabinoid receptor antagonists and inhibitors of endocannabinoid metabolism and transport, as well as mice deficient in cannabinoid receptors or the endocannabinoid-degrading enzyme fatty acid amidohydrolase.
In the past decade, the endocannabinoid system has been implicated in a growing number of physiological functions, both in the central and peripheral nervous systems and in peripheral organs. More importantly, modulating the activity of the endocannabinoid system turned out to hold therapeutic promise in a wide range of disparate diseases and pathological conditions, ranging from mood and anxiety disorders, movement disorders such as Parkinson’s and Huntington’s disease, neuropathic pain, multiple sclerosis and spinal cord injury, to cancer, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity/metabolic syndrome, and osteoporosis, to name just a few.’
Full overview ~ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2241751/
Copyright Disclaimer – allowance is made for “Fair Use” for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favor of fair use. No copyright infringement intended. All rights and credit go directly to its rightful owners.
source